Cantor Fitzgerald Downgrades Affimed Therapeutics (AFMD) to Neutral May 14, 2025 07:50AM
Affimed (AFMD) Receives Nasdaq Delisting Notice May 14, 2025 06:49AM
Affimed (AFMD) Files the Opening of Insolvency Proceedings May 13, 2025 08:17AM
Affimed Therapeutics (AFMD) PT Lowered to $0.39 at Leerink Partnersm, Downgrades to Market Perform May 13, 2025 06:21AM
Affimed (AFMD) Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients Apr 29, 2025 10:01AM


Apr 21, 2025 06:36AM Affimed (AFMD) Receives Nasdaq Non-compliance Notice+
Dec 18, 2024 06:46AM Affimed Therapeutics (AFMD) PT Lowered to $7 at H.C. Wainwright
Dec 17, 2024 08:04AM Truist Securities keeps Affimed Therapeutics (AFMD) at Buy, 'believe that PFS of 7 months might be needed for the combo to be competitive'
Dec 17, 2024 06:30AM Affimed (AFMD) Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
Dec 9, 2024 01:32PM Affimed (AFMD) Reports Phase 1 Efficacy and Safety Data for AFM28, The AFM28 Phase 1 study is on-going
Dec 5, 2024 06:30AM Affimed (AFMD) Announces Acimtamig and AlloNK Combination Granted FDA Regenerative Medicine Advanced Therapy Designation
Nov 15, 2024 07:29AM H.C. Wainwright Reiterates Buy Rating on Affimed Therapeutics (AFMD)
Nov 14, 2024 06:30AM Affimed (AFMD) Misses Q3 EPS by 9c
Sep 17, 2024 05:36AM Truist Securities Reiterates Buy Rating on Affimed Therapeutics (AFMD)
Sep 5, 2024 03:01PM Stifel Reiterates Hold Rating on Affimed Therapeutics (AFMD)
Sep 3, 2024 07:45AM Affimed (AFMD) Appoints Shawn M. Leland as CEO
Jun 12, 2024 04:00PM Affimed Therapeutics (AFMD) PT Raised to $25 at Laidlaw
Jun 12, 2024 06:36AM Affimed (AFMD) Tops Q1 EPS by 28c